One-year results of gastric peroral endoscopic myotomy for refractory gastroparesis: a French multicenter study

Abstract

Background: Data on the long-term outcomes of gastric peroral endoscopic myotomy (G-POEM) for refractory gastroparesis are lacking. We report the results of a large multicenter long-term follow-up study of G-POEM for refractory gastroparesis.

Methods: This was a retrospective multicenter study of all G-POEM operations performed in seven expert French centers for refractory gastroparesis with at least 1 year of follow-up. The primary endpoint was the 1-year clinical success rate, defined as at least a 1-point improvement in the Gastroparesis Cardinal Symptom Index (GCSI).

Results: 76 patients were included (60.5 % women; age 56 years). The median symptom duration was 48 months. The median gastric retention at 4 hours (H4) before G-POEM was 45 % (interquartile range [IQR] 29 % – 67 %). The median GCSI before G-POEM was 3.6 (IQR 2.8 – 4.0). Clinical success was achieved in 65.8 % of the patients at 1 year, with a median rate of reduction in the GCSI score of 41 %. In logistic regression analysis, only a high preoperative GCSI satiety subscale score was predictive of clinical success (odds ratio [OR] 3.41, 95 % confidence interval [CI] 1.01 – 11.54; P = 0.048), while a high rate of gastric retention at H4 was significantly associated with clinical failure (OR 0.97, 95 %CI 0.95 – 1.00; P = 0.03).

Conclusions: The results confirm the efficacy of G-POEM for the treatment of refractory gastroparesis, as evidenced by a 65.8 % clinical success rate at 1 year. Although G-POEM is promising, prospective sham-controlled trials are urgently needed to confirm its efficacy and identify the patient populations who will benefit most from this procedure.

• References

• 1 Camilleri M, Parkman HP, Shafi MA. et al. American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108: 18-37; quiz 38
• 2 de la Loge C, Trudeau E, Marquis P. et al. Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res 2004; 13: 1751-1762
• 3 Jung H-K, Choung RS, Locke GR. et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009; 136: 1225-1233
• 4 Soykan I, Sivri B, Sarosiek I. et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998; 43: 2398-2404
• 5 Shen S, Xu J, Lamm V. et al. Diabetic gastroparesis and nondiabetic gastroparesis. Gastrointest Endosc Clin N Am 2019; 29: 15-25
• 6 Cutts TF, Luo J, Starkebaum W. et al. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits?. Neurogastroenterol Motil 2005; 17: 35-43
• 7 Nusrat S, Bielefeldt K. Gastroparesis on the rise: incidence vs awareness?. Neurogastroenterol Motil 2013; 25: 16-22
• 8 Hyett B, Martinez FJ, Gill BM. et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 2009; 137: 445-452
• 9 Navas CM, Patel NK, Lacy BE. Gastroparesis: medical and therapeutic advances. Dig Dis Sci 2017; 62: 2231-2240
• 10 Liu N, Abell T. Gastroparesis updates on pathogenesis and management. Gut Liver 2017; 11: 579-589
• 11 Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986; 90: 1919-1925
• 12 Gourcerol G, Tissier F, Melchior C. et al. Impaired fasting pyloric compliance in gastroparesis and the therapeutic response to pyloric dilatation. Aliment Pharmacol Ther 2015; 41: 360-367
• 13 Geyl S, Legros R, Charissou A. et al. Peroral endoscopic pyloromyotomy accelerates gastric emptying in healthy pigs: proof of concept. Endosc Int Open 2016; 4: E796-E799
• 14 Khashab MA, Stein E, Clarke JO. et al. Gastric peroral endoscopic myotomy for refractory gastroparesis: first human endoscopic pyloromyotomy (with video). Gastrointest Endosc 2013; 78: 764-768
• 15 Gonzalez JM, Benezech A, Vitton V. et al. G-POEM with antro-pyloromyotomy for the treatment of refractory gastroparesis: mid-term follow-up and factors predicting outcome. Aliment Pharmacol Ther 2017; 46: 364-370
• 16 Jacques J, Pagnon L, Hure F. et al. Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. Endoscopy 2019; 51: 40-49
• 17 Kahaleh M, Gonzalez J-M, Xu M-M. et al. Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a multicenter international experience. Endoscopy 2018; 50: 1053-1058
• 18 Rodriguez JH, Haskins IN, Strong AT. et al. Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution. Surg Endosc 2017; 31: 5381-5388
• 19 Shlomovitz E, Pescarus R, Cassera MA. et al. Early human experience with per-oral endoscopic pyloromyotomy (POP). Surg Endosc 2015; 29: 543-551
• 20 Khashab MA, Ngamruengphong S, Carr-Locke D. et al. Gastric per-oral endoscopic myotomy for refractory gastroparesis: results from the first multicenter study on endoscopic pyloromyotomy (with video). Gastrointest Endosc 2017; 85: 123-128
• 21 Dacha S, Mekaroonkamol P, Li L. et al. Outcomes and quality-of-life assessment after gastric per-oral endoscopic pyloromyotomy (with video). Gastrointest Endosc 2017; 86: 282-289
• 22 Malik Z, Kataria R, Modayil R. et al. Gastric per oral endoscopic myotomy (G-POEM) for the treatment of refractory gastroparesis: early experience. Dig Dis Sci 2018; 63: 2405-2412
• 23 Xu J, Chen T, Elkholy S. et al. Gastric peroral endoscopic myotomy (G-POEM) as a treatment for refractory gastroparesis: long-term outcomes. Can J Gastroenterol Hepatol 2018; 2018: 6409698
• 24 Mekaroonkamol P, Dacha S, Wang L. et al. Gastric peroral endoscopic pyloromyotomy reduces symptoms, increases quality of life, and reduces health care use for patients with gastroparesis. Clin Gastroenterol Hepatol 2019; 17: 82-89
• 25 Mekaroonkamol P, Patel V, Shah R. et al. Association between duration or etiology of gastroparesis and clinical response after gastric per-oral endoscopic pyloromyotomy. Gastrointest Endosc 2019; 89: 969-976
• 26 Revicki DA, Rentz AM, Dubois D. et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res 2004; 13: 833-844
• 27 Abell TL, Camilleri M, Donohoe K. et al. American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103: 753-763
• 28 Camilleri M. Diabetic Gastroparesis. NEJM 2007; 356: 820-829
• 29 Parkman HP, Hallinan EK, Hasler WL. et al. Gastroparesis Clinical Research Consortium (GpCRC). Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol Motil 2017;
• 30 Vijayvargiya P, Jameie-Oskooei S, Camilleri M. et al. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut 2019; 68: 804-813
• 31 Xue HB, Fan HZ, Meng XM. et al. Fluoroscopy-guided gastric peroral endoscopic pyloromyotomy (G-POEM): a more reliable and efficient method for treatment of refractory gastroparesis. Surg Endosc 2017; 31: 4617-4624
• 32 Pasricha PJ, Yates KP, Sarosiek I. et al. Gastroparesis Clinical Research Consortium (GpCRC). Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders. Gastroenterology 2018; 154: 65-76.e11
• 33 Tack J, Rotondo A, Meulemans A. et al. Randomized clinical trial: a controlled pilot trial of the 5-HT receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. Neurogastroenterol Motil 2016; 28: 487-497
• 34 Camilleri M, McCallum RW, Tack J. et al. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology 2017; 153: 1240-1250.e2
• 35 Rodriguez J, Strong AT, Haskins IN. et al. Per-oral Pyloromyotomy (POP) for medically refractory gastroparesis: short term results from the first 100 patients at a high volume center. Annals of Surgery 2018; 268: 421-430
• 36 Hustak R, Vacková Z, Krajciova J. et al. Per-oral endoscopic pyloromyotomy (g-poem) for the treatment of gastroparesis – a pilot single-centre study with mid-term follow-up. Rozhl Chir 2020; 99: 116-123